Open in Screener

GPUS

Hyperscale Data Inc

Jun 12 • 04:00PM ET

0.1546

-0.0135 -8.03 %

Industrials • Aerospace & Defense • USA • Micro • AMEX

Jun 11, 4:20 PMHyperscale Data starts production of first 30 OPR-R2 humanoid robots for 143-robot Michigan AI data center deployment

Peers: BYRN CODA HOVR MOB OPXS SIF SPAI VWAV XTIA POWW

Index	-	P/E	-	EPS (ttm)	-3.24	Insider Own	1.01%	Shs Outstand	461.46M	Perf Week	2.38%
Market Cap	75.05M	Forward P/E	-	EPS next Y	-	Insider Trans	173.63%	Shs Float	456.79M	Perf Month	18.83%
Enterprise Value	158.12M	PEG	-	EPS next Q	-	Inst Own	6.82%	Short Float	5.99%	Perf Quarter	-5.44%
Income	-101.32M	P/S	0.62	EPS this Y	-	Inst Trans	-0.47%	Short Ratio	0.63	Perf Half Y	-47.59%
Sales	121.17M	P/B	0.59	EPS next Y	-	ROA	-34.25%	Short Interest	27.35M	Perf YTD	-15.80%
Book/sh	0.26	P/C	2.07	EPS next 5Y	-	ROE	-178.39%	52W High	4.62 -96.65%	Perf Year	-96.52%
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	98.43% 93.75%	ROIC	-80.89%	52W Low	0.11 36.45%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.61% 33.73%	Gross Margin	25.88%	Volatility	11.34% 15.07%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	1.30	EPS Y/Y TTM	95.16%	Oper. Margin	-48.79%	ATR (14)	0.02	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.50	Sales Y/Y TTM	16.59%	Profit Margin	-83.62%	RSI (14)	47.26	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.53	EPS Q/Q	91.31%	SMA20	-9.01%	Beta	2.62	Target Price	-
Payout	-	Debt/Eq	1.17	Sales Q/Q	76.17%	SMA50	0.78%	Rel Volume	0.65	Prev Close	0.17
Employees	612	LT Debt/Eq	0.17	Earnings	-	SMA200	-41.78%	Avg Volume	43.48M	Price	0.15
IPO	Dec 17, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	- -8.67%	Trades		Volume	28,047,988	Change	-8.03%

Jun-11-26 04:15PM	Hyperscale Data Confirms Production of First 30 Omnipresent Robotics OPR-R2 Humanoid Robots Has Begun (PR Newswire) -8.03%
04:00AM	Hyperscale Data Announces Transaction with Yorkville (PR Newswire)
Jun-10-26 06:00AM	Hyperscale Data, Inc. Announces Final Results for Tender Offer (PR Newswire)
Jun-09-26 06:00AM	Hyperscale Data, Inc. Announces Preliminary Results for Tender Offer (PR Newswire) -7.82%
05:00AM	Hyperscale Data Bitcoin Treasury Reaches Approximately 709 Bitcoin (PR Newswire)
06:00AM	Loading…
Jun-02-26 06:00AM	Hyperscale Data Bitcoin Treasury Reaches Approximately 704.3405 Bitcoin (PR Newswire) +30.60%
Jun-01-26 05:00AM	Hyperscale Data Subsidiary Ault Global Commodities Enters into Agreement with The Wyoming Reserve for Secure Precious Metals Storage and Vaulting (PR Newswire) -6.95%
May-28-26 08:20AM	GPUS Stock Dips After Hyperscale Data Halts Dilution For $5M Buyback Retail Rejoices (Stocktwits) +15.75%
06:30AM	Hyperscale Data Announces Termination of the Sales Agreement Providing for Its ATM Offering (PR Newswire)
May-26-26 11:20AM	Smaller Bitcoin Treasuries Add 603 BTC as Strategy Pauses Buying (CryptoProwl) +5.20%
08:58AM	Bitcoin Treasury Bet Sends GPUS Stock Higher Pre-Market Hyperscale Data Unveils Buyback Plan (Stocktwits)
06:00AM	Hyperscale Data, Inc. Commences Tender Offer to Repurchase up to $5 Million of Shares of Class A Common Stock (PR Newswire)
04:00AM	Hyperscale Data Bitcoin Treasury Reaches Approximately 700 Bitcoin (PR Newswire)
May-19-26 05:00AM	Hyperscale Data Bitcoin Treasury at Approximately 692 Bitcoin (PR Newswire) -5.41%
May-15-26 01:22PM	Hyperscale Data Announces Intent to Launch Tender Offer to Acquire Up to $5,000,000 of Outstanding Shares at $0.21 Per Share (PR Newswire) +16.80%
06:55AM	Loading…
May-12-26 06:55AM	Hyperscale Data Reports Approximately 687 Bitcoin and Approximately $94 Million of Combined Bitcoin, Cash and Restricted Cash; Plans to Discuss Major Capital Markets and Treasury Initiatives with First Quarter 2026 Results (PR Newswire)
May-11-26 04:30PM	Hyperscale Data's Subsidiary Omnipresent Robotics Enters into an Agreement Providing for the Acquisition of Robots from AGIBOT and Related Developments (PR Newswire)
07:15AM	Hyperscale Data Announces Progress Toward Leasing AI Compute Capacity at Michigan Data Center Campus and Evaluating Long-Term Expansion Opportunities (PR Newswire)
May-07-26 04:30PM	Hyperscale Data Evaluating Strategic Alternatives as Balance Sheet Strength Continues to Exceed Public Market Valuation (PR Newswire) -7.00%
06:00AM	Hyperscale Data Executive Chairman Milton "Todd" Ault III to Speak at Consensus 2026 about Ault Blockchain and Tokenized Commodities (PR Newswire)
May-06-26 06:00AM	Hyperscale Data to Expand Digital and Physical Asset Treasury with Planned Purchase of 2,000 Ounces of Gold (PR Newswire)
May-05-26 06:00AM	Hyperscale Data Bitcoin Treasury at 680.9595 Bitcoin Valued at $53.5 Million (PR Newswire)
May-04-26 05:00AM	Hyperscale Data to Launch 20-Week Business Spotlight Series to Highlight the Scale, Scope and Value of Its Operations (PR Newswire)
Apr-30-26 06:45AM	Hyperscale Data Announces Revised Preliminary First Quarter 2026 Revenue of Approximately $44 Million, Up 76% Year-Over-Year; Evaluating Increase to Previously Announced Full-Year Guidance of $180 Million to $200 Million (PR Newswire) +5.26%
Apr-28-26 06:00AM	Hyperscale Data Announces $53.1 Million in Bitcoin Holdings (PR Newswire)
Apr-27-26 04:30PM	Hyperscale Data Subsidiary Ault Global Commodities Announces First Silver Purchase (PR Newswire) -9.29%
06:30AM	Hyperscale Data Subsidiary Ault Global Commodities Partners with Scottsdale Mint to Advance Company's Precious Metals and Rare Earth Minerals Strategy (PR Newswire)
Apr-22-26 04:30PM	Hyperscale Data Sees Rising Demand Across Defense Portfolio Amid Heightened Global Activity (PR Newswire) +11.17% -9.93%
Apr-21-26 06:30AM	Hyperscale Data Exceeds $50 Million in Bitcoin Holdings for Second Time, Surpassing Halfway Mark Toward $100 Million Bitcoin Treasury Goal (PR Newswire)
Apr-20-26 06:00AM	Hyperscale Data Accelerates Michigan Operations Capabilities for AI Data Center and Robotics Hub (PR Newswire)
06:30AM	Loading…
Apr-17-26 06:30AM	Hyperscale Data Announces Strategic Partnership with AGIBOT for AI Robotics (PR Newswire) +5.21%
Apr-14-26 06:30AM	Hyperscale Data Reports 644.7581 Bitcoin, Cash and Restricted Cash, totalling $93.5 Million, Significantly Exceeding Current Market Capitalization of Company (PR Newswire)
Apr-07-26 04:15PM	Hyperscale Data, Inc. Announces Preliminary Q1 2026 Revenue of $43 Million to $45 Million, Reflecting Approximately 72% to 80% Year-Over-Year Growth (PR Newswire)
11:35AM	Hyperscale Data Reports $102M in Assets, Surpassing Market Value (CryptoProwl)
06:00AM	Hyperscale Data's $102 Million in Cash, Restricted Cash, and Bitcoin Holdings Significantly Exceed Current Market Capitalization of Company (PR Newswire)
Apr-02-26 06:00AM	Hyperscale Data Receives $26.6 Million of Cash Related to Litigation Settlement; Cash Receipt Represents a Significant Liquidity Event for the Company (PR Newswire) -7.23%
Mar-31-26 06:30AM	Hyperscale Data's $82.1 Million in Cash, Restricted Cash, and Bitcoin Holdings Significantly Exceed Current Market Capitalization of Company (PR Newswire) +7.43%
Mar-30-26 08:46AM	Hyperscale Data Expands Michigan AI Footprint With 48.5 Acre Acquisition (CryptoProwl)
06:30AM	Hyperscale Data Enters into Agreement to Expand Michigan AI Data Center Campus with 48.5 Acre Acquisition (PR Newswire)
Mar-24-26 08:00AM	Hyperscale Data Bitcoin Treasury at 627.8970 Bitcoin; Cash and Bitcoin Holdings at Approximately 147.07% of Market Capitalization (PR Newswire) -7.23%
Mar-20-26 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Mar-19-26 06:00AM	Hyperscale Data Launches Omnipresent Robotics (PR Newswire)
Mar-17-26 06:00AM	Hyperscale Data Bitcoin Treasury at 622.4378 Bitcoin; Cash and Bitcoin Holdings at Approximately 161.23% of Market Capitalization (PR Newswire)
Mar-12-26 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $0.87 and $0.33, Respectively, as of February 28, 2026 (PR Newswire) -5.92%
Mar-11-26 06:11AM	Hyperscale Data sees FY26 revenue $180M-$200M (TipRanks) +7.31%
06:00AM	Hyperscale Data Provides 2026 Revenue Guidance of $180 Million to $200 Million as Artificial Intelligence Infrastructure Scale-Up Continues and Higher Margin Platforms Expand (PR Newswire)
Mar-10-26 08:53AM	Hyperscale Data, Inc. (GPUS) Plans Strategic Silver Reserve Program (Insider Monkey)
06:00AM	Hyperscale Data Bitcoin Treasury at 617.1605 Bitcoin; Cash and Bitcoin Holdings at Approximately 137.98% of Market Capitalization (PR Newswire)
Mar-05-26 11:45AM	Crypto Currents: Bitcoin tops $71,000 as ETF inflows return (TipRanks)
06:00AM	Hyperscale Data's Subsidiary askROI Deploys Claude Opus 4.6 to Power Next-Generation Artificial Intelligence Reasoning, Agents and Enterprise Intelligence (PR Newswire)
Mar-03-26 06:00AM	Hyperscale Data Bitcoin Treasury at 610.9188 Bitcoin; Cash and Bitcoin Holdings at Approximately 141.93% of Market Capitalization (PR Newswire)
Feb-24-26 06:00AM	Hyperscale Data Bitcoin Treasury at 605.9923 Bitcoin; Cash and Bitcoin Holdings at Approximately 142.41% of Market Capitalization (PR Newswire)
Feb-23-26 09:00AM	This Penny Stock Is Building a Strategic Silver Reserve. Should You Buy Shares Now to Bet on a Run in Silver Prices? (Barchart)
Feb-19-26 06:00AM	Hyperscale Data Subsidiary askROI Surpasses 1,300,000 Downloads on Apple App and Google Play Stores (PR Newswire)
Feb-18-26 06:00AM	Hyperscale Data Announces Strategic Silver Reserve Program to Acquire up to 100,000 Ounces of Silver (PR Newswire)
Feb-17-26 06:00AM	Hyperscale Data Bitcoin Treasury at 600.5299 Bitcoin; Cash and Bitcoin Holdings at Approximately 136.82% of Market Capitalization (PR Newswire) -8.89%
Feb-13-26 04:30PM	Hyperscale Data Announces "At-the-Market" Offering of Preferred Stock (PR Newswire)
Feb-10-26 06:00AM	Hyperscale Data Bitcoin Treasury at 589.4502 Bitcoin (PR Newswire)
Feb-06-26 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $0.90 and $0.35, Respectively, as of January 31, 2026 (PR Newswire) +16.42%
Feb-03-26 06:00AM	Hyperscale Data Bitcoin Treasury at 575.5418 Bitcoin; Cash and Bitcoin Holdings at Approximately 142.78% of Market Capitalization (PR Newswire)
Feb-02-26 06:00AM	Hyperscale Data Reaffirms Digital Asset Treasury Policy Amid Bitcoin Volatility; Continues Weekly Dollar-Cost-Averaging Purchases (PR Newswire)
Jan-27-26 06:00AM	Hyperscale Data Bitcoin Treasury at 560.0363 Bitcoin (PR Newswire)
Jan-20-26 06:00AM	Hyperscale Data Bitcoin Treasury at 545.4218 Bitcoin (PR Newswire) -8.75%
Jan-16-26 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Jan-14-26 06:00AM	Hyperscale Data Announces 43 Consecutive Months of Cash Dividend Payments Timely Paid on its Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Jan-13-26 06:00AM	Hyperscale Data Bitcoin Treasury at 539.5929 Bitcoin (PR Newswire)
Jan-07-26 04:38PM	Popular AI stock jumps 30% as Bitcoin treasury exceeds market cap (TheStreet) +40.67%
06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $1.14 and $0.50, Respectively, as of December 31, 2025 (PR Newswire)
Jan-06-26 06:00AM	Hyperscale Data Bitcoin Treasury at 532.6978 Bitcoin and Held Approximately $43.1 Million of Cash as of January 2, 2026 (PR Newswire)
Jan-02-26 06:59PM	AI stock jumps 60% after SEC filing reveals insider buying (TheStreet) +48.69% -10.62%
Dec-30-25 06:00AM	Hyperscale Data Bitcoin Treasury at 519.8687 Bitcoin and Held Approximately $47 Million of Cash as of December 26, 2025 (PR Newswire)
Dec-29-25 06:00AM	Hyperscale Data Establishes 2026 Disclosure Schedule for Bitcoin Treasury, Michigan AI Data Center Progress and Monthly Estimated Asset Updates (PR Newswire) -9.14%
Dec-23-25 06:00AM	Hyperscale Data Bitcoin Treasury at 514.9655 Bitcoin and Exceeds 100% of Market Capitalization (PR Newswire)
Dec-19-25 04:30PM	Hyperscale Data Announces "At-the-Market" Offering of Common Stock (PR Newswire) -9.10%
Dec-17-25 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire)
Dec-16-25 08:42AM	Hyperscale Data and American Bitcoin Expand Corporate Bitcoin Treasuries (Cryptonews)
06:00AM	Hyperscale Data Bitcoin Treasury at 97.5% of Market Capitalization at Approximately $75.5 Million (PR Newswire)
Dec-15-25 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $1.17 and $0.52, Respectively, as of November 30, 2025 (PR Newswire) -5.20%
Dec-09-25 06:00AM	Hyperscale Data Bitcoin Treasury at Approximately $75 Million (PR Newswire) +7.18%
Dec-02-25 06:00AM	Hyperscale Data Bitcoin Treasury at Approximately $72.25 Million (PR Newswire) +6.45%
Nov-25-25 06:00AM	Hyperscale Data Bitcoin Treasury at Approximately $70.5 Million (PR Newswire)
Nov-24-25 06:00AM	Hyperscale Data Joins the Global Top 100 Public Bitcoin Treasury Companies with Current Holdings of Approximately 382 Bitcoin (PR Newswire) +12.38%
Nov-18-25 04:30PM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire) -6.04%
06:00AM	Hyperscale Data Bitcoin Treasury At Approximately $72.5 Million Representing Approximately 94% of Market Capitalization (PR Newswire)
Nov-17-25 06:00AM	Hyperscale Data Releases Early Bitcoin Update in Light of Market Volatility; the Company Purchased Approximately $6 Million of Bitcoin during November 10-14, 2025 (PR Newswire) -14.84%
Nov-14-25 06:00AM	Hyperscale Data Issues Letter to Stockholders from Executive Chairman (PR Newswire) -7.60%
Nov-12-25 06:00AM	Hyperscale Data Deploying 4,092 New Generation Bitmain Bitcoin Miners, Accelerating Bitcoin Production and Advancing Company Goal of $100 Million Bitcoin Treasury Strategy (PR Newswire)
Nov-11-25 06:00AM	Hyperscale Data Bitcoin Treasury Rises to $75.25 Million (PR Newswire)
Nov-06-25 06:00AM	Hyperscale Data Announces Estimated Total Assets and Net Assets per Share of $1.02 and $0.47, Respectively, as of October 31, 2025 (PR Newswire)
Nov-05-25 06:00AM	Hyperscale Data Announces Completion of $125 Million At-The-Market Program, Strengthening Its Position as a Bitcoin-Anchored AI Infrastructure Platform Provider (PR Newswire) +11.62%
Nov-04-25 10:11AM	Hyperscale Data Nears $100M Bitcoin Treasury Target With $73.5M in Holdings (CoinGape) -7.03%
06:00AM	Hyperscale Data Bitcoin Treasury Grows to $73.5 Million (PR Newswire)
Oct-29-25 06:30AM	Hyperscale Data Expands Bitcoin Mining Capacity with Order of 2,000 Bitmain S21 Pro Bitcoin Miners (PR Newswire) -18.58%
Oct-28-25 06:30AM	Hyperscale Data Bitcoin Treasury Climbs to $68.8 Million (PR Newswire) +10.16%
Oct-23-25 06:00AM	Hyperscale Data to Launch On-Demand NVIDIA GPU Cloud from Michigan AI Campus (PR Newswire)
Oct-22-25 06:30AM	Hyperscale Data Regains Compliance with NYSE American Continued Listing Standards (PR Newswire)
Oct-21-25 06:00AM	Hyperscale Data Bitcoin Treasury Climbs to $60 Million (PR Newswire) -7.57%
Oct-17-25 06:00AM	Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock (PR Newswire) -11.97%
Oct-16-25 06:00AM	Hyperscale Data Takes Delivery of 1,000 Bitmain Antminer S21+ Units and Orders an Additional 1,000 Units (PR Newswire) -5.78%
Oct-14-25 06:00AM	Hyperscale Data Progresses Toward 100% Bitcoin Pairing as Digital Asset Treasury Climbs to $54 Million (PR Newswire) -5.58%

Hyperscale Data, Inc. owns and manages a data center and provides mission-critical products for the defense and aerospace, industrial, automotive, telecommunications, medical and biopharma, and textile industries. It operates through the following segments: Sentinum, Energy and Infrastructure, AGREE, Gresham, TurnOnGreen, Technology and Finance, and ROI. The Sentinum segment involves crypto asset mining operations, colocation and hosting services for emerging AI ecosystems and other industries, and digital asset treasury activities. The Energy and Infrastructure segment involves crane rental and lifting solutions provider for oilfield, construction, commercial and infrastructure markets. The AGREE segment involves hotel operations and other commercial real estate holdings. The Gresham segment involves defense solutions with operations conducted by Enertec, Relec, Microphase and Giga-tronics. The TurnOnGreen segment involves commercial electronics solutions with operations conducted by Digital Power, and electric vehicle ("EV") charging solutions through TOG Technologies. The Technology and Finance segment involves commercial lending and trading through Ault Lending. The ROI segment involves askROI, which operates OnlyBulls, a consumer-facing financial research and market intelligence platform developed and operated by askROI as well as ROI's own operations. The company was founded by Milton C. Ault III in 1969 and is headquartered in Las Vegas, NV.

Founder & Executive ChairmanMr. Milton Charles Ault III

CEO & Vice ChairmanMr. William B. Horne

PresidentMr. Henry C. W. Nisser Esq.

Chief Financial OfficerMr. Kenneth S. Cragun CPA

Chief Accounting OfficerMs. Jean Ho

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horne William B.	Chief Executive Officer	Jun 11 '26	Buy	0.17	200,000	33,760	200,000	Jun 12 04:30 PM
AULT MILTON C III	Executive Chairman	Jun 11 '26	Buy	0.16	100,000	15,940	2,700,005	Jun 12 04:30 PM
AULT MILTON C III	Executive Chairman	Jun 10 '26	Buy	0.17	40,000	6,648	706,300	Jun 12 04:30 PM
AULT MILTON C III	Executive Chairman	Jun 11 '26	Buy	0.16	15,000	2,451	721,300	Jun 12 04:30 PM
AULT MILTON C III	Executive Chairman	May 28 '26	Buy	21.19	100	2,119	100	May 29 04:30 PM
AULT MILTON C III	Executive Chairman	May 19 '26	Buy	0.13	397,500	52,390	666,300	May 20 07:30 PM
AULT MILTON C III	Executive Chairman	May 19 '26	Buy	0.13	100,000	13,430	2,600,005	May 20 07:30 PM
AULT MILTON C III	Executive Chairman	Dec 31 '25	Buy	0.18	1,000,000	182,900	2,500,005	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 30 '25	Buy	0.19	500,000	94,700	1,500,005	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 30 '25	Buy	0.19	60,000	11,544	220,000	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 31 '25	Buy	0.18	48,800	8,965	268,800	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 29 '25	Buy	22.83	33	753	149	Jan 02 06:08 AM
AULT MILTON C III	Executive Chairman	Dec 29 '25	Buy	0.20	100,000	20,290	1,000,005	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 29 '25	Buy	0.22	59,483	12,804	160,000	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 23 '25	Buy	0.23	10,000	2,250	85,550	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 26 '25	Buy	0.21	10,000	2,140	100,550	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 24 '25	Buy	0.23	5,000	1,128	90,550	Dec 30 05:27 PM
AULT MILTON C III	Executive Chairman	Dec 22 '25	Buy	0.23	200,000	46,640	900,005	Dec 23 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 19 '25	Buy	0.23	100,000	23,290	700,005	Dec 23 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 19 '25	Buy	0.23	15,000	3,393	75,550	Dec 23 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 16 '25	Buy	0.25	5,000	1,267	55,550	Dec 18 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 17 '25	Buy	0.25	5,000	1,246	60,550	Dec 18 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 15 '25	Buy	0.26	125,100	32,426	600,005	Dec 16 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 15 '25	Buy	0.24	12,000	2,918	50,550	Dec 16 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 12 '25	Buy	0.27	3,000	804	38,550	Dec 16 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 10 '25	Buy	0.29	5,000	1,462	30,550	Dec 12 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 11 '25	Buy	0.29	5,000	1,442	35,550	Dec 12 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 03 '25	Buy	0.28	100,000	27,770	474,905	Dec 05 05:00 PM
AULT MILTON C III	Executive Chairman	Dec 01 '25	Buy	0.27	100,000	27,410	374,905	Dec 03 04:30 PM
AULT MILTON C III	Executive Chairman	Dec 02 '25	Buy	0.29	1,000	292	25,550	Dec 03 04:30 PM
AULT MILTON C III	Executive Chairman	Nov 26 '25	Buy	0.29	1,000	294	24,550	Dec 01 04:30 PM
AULT MILTON C III	Executive Chairman	Nov 18 '25	Buy	0.24	205,656	48,782	224,905	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Nov 19 '25	Buy	0.23	50,000	11,450	274,905	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Nov 18 '25	Buy	0.24	3,800	898	23,550	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Sep 11 '25	Buy	0.37	500	185	19,750	Nov 20 05:40 PM
AULT MILTON C III	Executive Chairman	Sep 30 '25	Buy	0.43	2,012	862	19,250	Sep 30 07:15 PM
AULT MILTON C III	Executive Chairman	Sep 26 '25	Buy	0.45	688	307	17,238	Sep 30 07:15 PM
AULT MILTON C III	Executive Chairman	Sep 23 '25	Buy	0.39	1,000	388	16,050	Sep 25 05:00 PM
AULT MILTON C III	Executive Chairman	Sep 24 '25	Buy	0.42	500	209	16,550	Sep 25 05:00 PM
AULT MILTON C III	Executive Chairman	Sep 15 '25	Buy	0.52	6,000	3,099	12,050	Sep 17 08:48 PM
AULT MILTON C III	Executive Chairman	Sep 17 '25	Buy	0.40	3,000	1,211	15,050	Sep 17 08:48 PM
Hyperscale Data, Inc.	10% Owner	Aug 28 '25	Buy	0.01	1,000,000	6,600	13,806,817	Sep 10 07:00 PM
AULT MILTON C III	Executive Chairman	Sep 08 '25	Buy	0.40	2,600	1,050	5,050	Sep 10 07:00 PM
AULT MILTON C III	Executive Chairman	Sep 09 '25	Buy	0.38	1,000	375	6,050	Sep 10 07:00 PM
AULT MILTON C III	Executive Chairman	Aug 22 '25	Buy	0.57	100	57	2,450	Aug 27 04:30 PM
AULT MILTON C III	Executive Chairman	Aug 20 '25	Buy	0.57	10,000	5,724	19,249	Aug 21 05:31 PM
AULT MILTON C III	Executive Chairman	Aug 20 '25	Buy	0.55	1,550	845	2,350	Aug 21 05:31 PM
AULT MILTON C III	Executive Chairman	Aug 19 '25	Buy	0.60	200	120	800	Aug 21 05:31 PM
AULT MILTON C III	Executive Chairman	Jun 17 '25	Buy	1.72	1,000	1,722	9,249	Jun 17 09:42 PM
AULT MILTON C III	Executive Chairman	Jun 17 '25	Buy	2.00	100	200	600	Jun 17 09:42 PM

Open in Screener

ALZN

Alzamend Neuro Inc

Jun 12 • 04:00PM ET

1.21

+0.07 5.68 %

Healthcare • Biotechnology • USA • Nano • NASD

ALZN Alzamend Neuro Inc daily Stock Chart

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-4.38	Insider Own	16.05%	Shs Outstand	3.80M	Perf Week	9.01%
Market Cap	4.60M	Forward P/E	-	EPS next Y	-2.60	Insider Trans	20.32%	Shs Float	3.19M	Perf Month	16.35%
Enterprise Value	1.89M	PEG	-	EPS next Q	-0.67	Inst Own	3.04%	Short Float	4.67%	Perf Quarter	-40.69%
Income	-7.63M	P/S	-	EPS this Y	75.82%	Inst Trans	-1.12%	Short Ratio	1.16	Perf Half Y	-43.98%
Sales	0.00M	P/B	2.11	EPS next Y	-0.78%	ROA	-171.39%	Short Interest	0.15M	Perf YTD	-33.52%
Book/sh	0.57	P/C	1.70	EPS next 5Y	-	ROE	-249.97%	52W High	3.60 -66.39%	Perf Year	-62.07%
Cash/sh	0.71	P/FCF	-	EPS past 3/5Y	60.75% 30.49%	ROIC	-322.36%	52W Low	0.84 44.05%	Perf 3Y	-99.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.45% 7.03%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	84.12%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.99	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.99	EPS Q/Q	65.91%	SMA20	6.49%	Beta	0.14	Target Price	25.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	12.16%	Rel Volume	0.48	Prev Close	1.14
Employees	7	LT Debt/Eq	0.00	Earnings	Mar 19	SMA200	-36.23%	Avg Volume	128.72K	Price	1.21
IPO	Jun 15, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-9.43% -	Trades		Volume	61,211	Change	5.68%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy	$8

Apr-07-26 08:00AM	Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital (PR Newswire)
Mar-26-26 08:00AM	Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions (PR Newswire) -22.28%
Mar-16-26 08:00AM	Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital (PR Newswire)
Jan-26-26 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-08-26 09:40AM	Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
07:50AM	Loading…
Nov-20-25 07:50AM	EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? (Zacks) -14.72%
Nov-19-25 08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital (PR Newswire) -5.33%
07:30AM	EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants (Benzinga)
Jul-28-25 08:00AM	Alzamend Neuro to Present at the 2025 Military Health System Research Symposium (GlobeNewswire) -6.42%
Jul-23-25 08:00AM	Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs (GlobeNewswire) -5.94%
Jun-16-25 08:00AM	Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule (GlobeNewswire)
May-29-25 08:00AM	Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +63.86%
May-19-25 08:00AM	Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) +5.88%
May-13-25 08:00AM	Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital (GlobeNewswire) -18.83%
07:30AM	EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants (Benzinga)
08:00AM	Loading…
May-08-25 08:00AM	Alzamend Neuro Announces Reverse Stock Split (GlobeNewswire) -9.40%
May-07-25 08:00AM	Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital (GlobeNewswire) -6.22%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program (Benzinga)
Apr-08-25 09:55AM	Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) -5.24%
Mar-28-25 10:42AM	Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-18-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital (GlobeNewswire) +5.03%
Mar-11-25 08:00AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Mar-04-25 08:10AM	Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital (GlobeNewswire)
Feb-25-25 08:00AM	Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital (GlobeNewswire)
07:30AM	EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 (Benzinga)
Feb-19-25 08:00AM	Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital (Business Wire) -6.48%
07:30AM	EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels (Benzinga)
Jan-23-25 09:40AM	Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-15-25 08:00AM	Alzamend Neuro to Present at the Sequire Investor Summit (Business Wire)
08:00AM	Loading…
Dec-18-24 08:00AM	Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo (Business Wire)
Dec-13-24 08:15AM	Alzamend Neuro says net cash gained by financing activity $8.3M (TipRanks)
Dec-12-24 08:00AM	Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs (Business Wire)
Nov-19-24 08:00AM	Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
Oct-16-24 08:00AM	Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
Oct-15-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaq Listing Standards (Business Wire)
Oct-10-24 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference (Business Wire)
Aug-26-24 08:00AM	Alzamend Neuro Issues Letter to Stockholders (Business Wire) -7.47%
Aug-19-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder (Business Wire) +186.78%
Aug-12-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder (Business Wire)
Aug-06-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder (Business Wire) -9.84%
05:32AM	Alzamend Neuro partners with Mass General for Alzheimers treatment trial (Clinical Trials Arena)
Aug-05-24 09:09AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimers Disease (Business Wire) -22.09%
07:30AM	EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
Jul-31-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Jul-12-24 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire)
May-22-24 08:00AM	Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Business Wire)
May-14-24 08:00AM	Alzamend Neuro Announces Initial Closing of Private Placement (Business Wire) +18.81%
May-09-24 09:30AM	EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga) +11.74%
08:00AM	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Business Wire)
May-07-24 08:00AM	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Business Wire) -20.02%
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-26-24 05:52AM	ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 (InvestorPlace)
Dec-18-23 12:03PM	ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024 (InvestorPlace)
12:03PM	ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024 (InvestorPlace)
Dec-11-23 09:30AM	EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year (Benzinga) -6.54%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Business Wire)
Nov-20-23 08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Business Wire) -17.75%
Nov-16-23 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Nov-13-23 08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire) -6.85%
Oct-30-23 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire) -24.62%
Oct-23-23 09:31AM	EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire)
Oct-02-23 09:30AM	EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder (Benzinga) -8.48%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Sep-22-23 08:00AM	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Business Wire)
Aug-30-23 09:30AM	EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Jun-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study (Benzinga)
08:00AM	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Business Wire)
Jun-13-23 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Groups Virtual Healthcare Conference (Business Wire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) +10.30%
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
Apr-04-23 06:30AM	Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Apr-03-23 09:35AM	KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) +15.29%
09:34AM	EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine (Benzinga)
08:50AM	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Mar-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial (Benzinga)
08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-17-23 07:09AM	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully (Simply Wall St.) -12.36%
Mar-16-23 08:00AM	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Business Wire)
Jan-26-23 08:00AM	Alzamend Neuro to Present at Sequire Biotechnology Conference (Business Wire) +9.48%
Jan-04-23 08:00AM	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Business Wire)
Dec-28-22 08:00AM	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) -11.31%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia (Benzinga)
Dec-13-22 03:52PM	10 Biotech Stocks With The Biggest Upside (Insider Monkey)
Nov-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. (ACCESSWIRE) +10.62%
Nov-15-22 08:00AM	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Business Wire)
Oct-31-22 08:00AM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Oct-11-22 10:03AM	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies (Simply Wall St.) -11.19%
Oct-05-22 12:45PM	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial (Benzinga) +7.25%
08:00AM	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimers Subjects (Business Wire)
Sep-29-22 12:29PM	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Sep-22-22 08:00AM	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Business Wire) -7.63%
Aug-25-22 07:13AM	We Think Alzamend Neuro (NASDAQ:ALZN) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jul-18-22 10:42AM	Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate (Benzinga)

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

CEO & DirectorMr. Stephan Jackman

Founder & Vice ChairmanMr. Milton Charles Ault III

Chief Financial OfficerMr. David J. Katzoff

Executive VPMr. Henry C. W. Nisser Esq.

Senior Vice President of FinanceMr. Kenneth S. Cragun CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	Director	Apr 14 '26	Buy	1.00	108,388	108,897	116,648	Apr 16 04:30 PM
AULT MILTON C III	Director	Dec 23 '25	Sale	2.07	1,851	3,825	0	Dec 30 05:54 PM
Horne William B.	Director	Dec 19 '25	Sale	2.12	3,333	7,059	0	Dec 23 04:30 PM
McGrath Lynne Fahey	Director	Oct 23 '25	Sale	2.29	30	69	25	Oct 24 04:30 PM
AULT MILTON C III	Director	Oct 08 '25	Sale	2.44	101,394	247,158	28,657	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 09 '25	Sale	2.32	20,397	47,390	8,260	Oct 10 04:30 PM
AULT MILTON C III	Director	Oct 06 '25	Sale	2.45	82,033	201,268	26,227	Oct 08 06:50 AM
AULT MILTON C III	Director	Oct 07 '25	Sale	2.49	57,379	142,954	68,848	Oct 08 06:50 AM
AULT MILTON C III	Director	Oct 03 '25	Sale	2.44	65,903	160,889	8,260	Oct 03 09:35 PM
AULT MILTON C III	Director	Oct 01 '25	Sale	2.35	36,777	86,378	94,849	Oct 03 09:35 PM
AULT MILTON C III	Director	Oct 02 '25	Sale	2.39	20,686	49,522	74,163	Oct 03 09:35 PM
AULT MILTON C III	Director	Sep 29 '25	Sale	2.31	38,324	88,490	35,192	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 26 '25	Sale	2.31	37,738	87,345	73,516	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 30 '25	Sale	2.33	3,566	8,321	31,626	Sep 30 07:15 PM
AULT MILTON C III	Director	Sep 23 '25	Sale	2.38	43,238	102,721	65,022	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 24 '25	Sale	2.31	39,140	90,374	25,882	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 25 '25	Sale	2.31	14,628	33,829	11,254	Sep 25 08:59 PM
AULT MILTON C III	Director	Sep 19 '25	Sale	2.35	77,009	180,856	8,260	Sep 23 04:30 PM
AULT MILTON C III	Director	Sep 18 '25	Sale	2.47	20,870	51,493	85,269	Sep 19 04:50 PM
AULT MILTON C III	Director	Sep 17 '25	Sale	2.45	2,121	5,204	106,139	Sep 19 04:50 PM
AULT MILTON C III	Director	Jul 31 '25	Sale	2.22	100,000	221,550	8,260	Aug 01 04:30 PM
AULT MILTON C III	Director	Jul 30 '25	Sale	2.51	29,449	73,982	108,260	Aug 01 04:30 PM
AULT MILTON C III	Director	Jul 25 '25	Sale	2.90	36,532	105,855	46,020	Jul 29 04:55 PM
AULT MILTON C III	Director	Jul 28 '25	Sale	2.68	8,311	22,314	37,709	Jul 29 04:55 PM
AULT MILTON C III	Director	Jul 23 '25	Sale	2.95	59,516	175,584	92,173	Jul 25 08:00 PM
AULT MILTON C III	Director	Jul 24 '25	Sale	2.93	9,621	28,237	82,552	Jul 25 08:00 PM

GPUS

Hyperscale Data Inc

ALZN

Alzamend Neuro Inc

Upgrade your Finviz experience